Gut

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Botta, F
Right arrow Articles by Testa, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Botta, F
Right arrow Articles by Testa, R
Gut 2003;52:134-139
© 2003 by Gut


LIVER DISEASE

MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study

F Botta1,*, E Giannini1,*, P Romagnoli1, A Fasoli1, F Malfatti1, B Chiarbonello1, E Testa1, D Risso2, G Colla3, R Testa1

1 Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Italy
2 Department of Health Science, University of Genoa, Genoa, Italy
3 Department of Laboratory Medicine, S Martino Hospital, Genoa, Italy

Correspondence to:
Correspondence to:
Professor R Testa, Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Viale Benedetto XV, No 6, 16132 Genoa, Italy;
rtesta{at}unige.it

Background: Indices for predicting survival are essential for assessing prognosis and assigning priority for liver transplantation in patients with liver cirrhosis. The model for end stage liver disease (MELD) has been proposed as a tool to predict mortality risk in cirrhotic patients. However, this model has not been validated beyond its original setting.

Aim: To evaluate the short and medium term survival prognosis of a European series of cirrhotic patients by means of MELD compared with the Child-Pugh score. We also assessed correlations between the MELD scoring system and the degree of impairment of liver function, as evaluated by the monoethylglycinexylidide (MEGX) test.

Patients and methods: We retrospectively evaluated survival of a cohort of 129 cirrhotic patients with a follow up period of at least one year. The Child-Pugh score was calculated and the MELD score was computed according to the original formula for each patient. All patients had undergone a MEGX test. Multivariate analysis was performed on all variables to identify the parameters independently associated with one year and six month survival. MELD values were correlated with both Child-Pugh scores and MEGX test results.

Results: Thirty one patients died within the first year of follow up. Child-Pugh and MELD scores, and MEGX serum levels were significantly different among patients who survived and those who died. Serum creatinine, international normalised ratio, and MEGX60 were independently associated with six month mortality while the same variables and the presence of ascites were associated with one year mortality. MELD scores showed significant correlations with both MEGX values and Child-Pugh scores.

Conclusions: In a European series of cirrhotic patients the MELD score is an excellent predictor of both short and medium term survival, and performs at least as well as the Child-Pugh score. An increase in MELD score is associated with a decrease in residual liver function.


Keywords: cirrhosis; liver function; ascites; creatinine; Child-Pugh score; MELD; MEGX

Abbreviations: OLT, orthotopic liver transplantation; MEGX, monoethylglycinexylidide; MELD, model for end stage liver disease; TIPSS, transjugular intrahepatic portosystemic stent shunt; INR, international normalised ratio; HCV, hepatitis C virus; HBV, hepatitis B virus; HDV, hepatitis D virus; ROC, receiver operating characteristic; SS, sensitivity; SP, specificity; RR, relative risk




This article has been cited by other articles:


Home page
GutHome page
M.-C. Londono, A. Cardenas, M. Guevara, L. Quinto, D. d. l. Heras, M. Navasa, A. Rimola, J.-C. Garcia-Valdecasas, V. Arroyo, and P. Gines
MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation
Gut, September 1, 2007; 56(9): 1283 - 1290.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
B. Lambert, K. Bacher, K. De Keukeleire, P. Smeets, I. Colle, J. M. Jeong, H. Thierens, R. Troisi, F. De Vos, and C. Van de Wiele
188Re-HDD/Lipiodol for Treatment of Hepatocellular Carcinoma: A Feasibility Study in Patients with Advanced Cirrhosis
J. Nucl. Med., August 1, 2005; 46(8): 1326 - 1332.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
E. G. Giannini, R. Testa, and V. Savarino
Liver enzyme alteration: a guide for clinicians
Can. Med. Assoc. J., February 1, 2005; 172(3): 367 - 379.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2003 BMJ Publishing Group Ltd & British Society of Gastroenterology